🧬 In this overview, Biovie Inc. (Nasdaq: BIVI) CEO Cuong Do recaps two Phase 2 clinical trial readouts BioVie has delivered within roughly 30 days of each other, both for lead candidate bezisterim. The first, in Parkinson's disease, shows the drug's potential to address both motor and non-motor symptoms — a distinction Do frames as significant, since most Parkinson's treatments target motor symptoms alone. He also points to the possibility that bezisterim could become the first drug to modify the disease's progression rather than just manage symptoms. The second readout, in Long COVID, found that patients experienced statistically significant, clinically meaningful improvement across fatigue, malaise, and brain fog. Looking ahead, Do says BioVie will continue analyzing the data from both trials and begin engaging with the FDA on Phase 3 trial design for both the Parkinson's and Long COVID programs. 🔗 Watch the overview: https://t.co/qGEYQZ07UN Biovie Inc. is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN